These apCAFs subsequently recruit FOXP1+ regulatory T cells through PD-L2-RGMB interactions, contributing to neoadjuvant immunotherapy resistance in early-stage lung cancer [64]. This evidence concerns the gene FOXP1 and lung carcinoma.